title: Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women.
abstract: OBJECTIVE
  To review the outcome in patients with atypical endometrial hyperplasia (AEH) and endometrial cancer (EC) who received MPA treatment in the present hospital.
  
  
  METHODS
  Patients with AEH or EC were administered MPA for 12 weeks followed by endometrial curettage. The rates of effect, recurrence, pregnancy, and complications were evaluated. The changes in progesterone receptors and FOXO-1, known as a target of MPA treatment, were examined by immunostaining.
  
  
  RESULTS
  Four of seven patients with endometrial cancer and three of three patients with AH had complete response. Four of seven patients had recurred within one year after the treatment and had to undergo hysterectomy. None of the patients showed changes in progesterone receptors. Although six of seven patients were negative for FOXO-1 before and after treatment, all the patients showed increased developments of FOXO-1 during MPA treatment.
  
  
  CONCLUSIONS
  Progestin as a fertility-preserving treatment is expected to be effective for endometrial cancer, but judicious use might be required because it shows high rate of recurrence. Further studies regarding the mechanism may be necessary to achieve high efficacy.
authors.forename: H
authors.initials: H
authors.lastname: Kataoka
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Sawada
authors.forename: H
authors.initials: H
authors.lastname: Kuroboshi
authors.forename: H
authors.initials: H
authors.lastname: Tatsumi
authors.forename: K
authors.initials: K
authors.lastname: Iwasaku
authors.forename: J
authors.initials: J
authors.lastname: Kitawaki
mesh_terms: D000328:Adult; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000378:metabolism; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D059247:Fertility Preservation / Q000379:methods*; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors / Q000032:analysis / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007564:Japan; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D059351:Organ Sparing Treatments / Q000379:methods*; D011980:Receptors, Progesterone / Q000032:analysis / Q000737:chemistry / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: C085126:FOXO1 protein, human; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors; D011980:Receptors, Progesterone; D017258:Medroxyprogesterone Acetate